



































The global prevalence of type 2 diabetes mellitus 
(T2DM) is rapidly growing as a consequence of life-
style changes, urbanization and population aging [1]. 
The increase of life expectancy in parallel with 
increasing risk of developing T2DM with advancing 
age is a significant driver of the diabetes epidemic [2-4]. 
Although elderly diabetic patients are widely 
represented in the clinical practice, focus on diabetes 
care in this age group is still relatively scarce, while the 
momentum for more clinical trials including older 
patients should be encouraged. In this regard, a recent 
analysis showed that only 0.6% of interventional trials 
in diabetes specifically targeted elderly patients, 30.8% 
excluded patients older than 65 years and the majority 
excluded those aged >75 years [5]. Therefore, an 
important limiting factor for producing specific 
evidence-based clinical guidelines for older people with 
diabetes is the need  to  extrapolate  evidence  from  data  
 
 

































obtained from younger adults. Moreover, the general 
viewpoint is that people aged 60+ years are part of the 
older population and the terms ‘elderly’ and ‘older 
people’ are often interchangeable; however, this 
definition can be quite arbitrary and misleading. While 
an age thresholds could be used to identify geriatric age, 
the connotation of the geriatric patient comes from a 
more “comprehensive” definition that must include the 
functional status, the number and severity of 
comorbidities, societal and economic parameters, and 
overall degree of frailty [6]. Therefore, the optimal 
management of diabetes in the elderly population must 
recognize the vast heterogeneity to which disease 
duration, diabetes complications, functional status, 
comorbid illnesses, and patient’s setting contribute to 
modulate the degree of vulnerability [7]. Elderly 
diabetic patients frequently have functional disabilities, 
cognitive decline, increased rates of bone fracture, 
polypharmacy, and hypoglycemic events due to 
comorbid illnesses. It is known that diabetic patients 
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factors  contribute  to  the high  prevalence  of  diabetes  in  the  elderly.  Clinical management of  T2DM  in  elderly  subjects
presents unique  challenges because of  the multifaceted  geriatric  scenario. Diabetes  significantly  lowers  the  chances of
“successful”  aging,  notably  it  increases  functional  limitations  and  impairs  quality  of  life.  In  this  regard,  older  diabetic
patients have a high burden of comorbidities, diabetes‐related complications, physical disability, cognitive impairment and
malnutrition, and they are more susceptible to the complications of dysglycemia and polypharmacy. Several national and
international organizations have delivered guidelines  to  implement optimal  therapy  in older diabetic patients based on
individualized  treatment  goals.  This  means  appreciation  of  the  heterogeneity  of  the  disease  as  generated  by  life
expectancy, functional reserve, social support, as well as personal preference. This paper will review current treatments
for achieving glycemic  targets  in elderly diabetic patients, and discuss  the potential  role of emerging  treatments  in  this
patient population. 
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with macrovascular complications are more susceptible 
to develop frailty, which, in turn, is associated with 
increased mortality [8]. Moreover, elderly patients may 
move in and out states of illness and functional 
impairment on a regular basis [9]. All these factors 
contribute to make the optimal therapy of T2DM in 
geriatric patients a controversial challenge [10] and 
advocate for a personalized approach [4,11]. This view 
is in line with the modern overall approach to T2DM 
management [12,13]. Position statement of the 
American Diabetes Association (ADA) and the 
European Association for the Study of Diabetes 
(EASD) has recently suggested an individualized and 
tailored care for T2DM, taking into account several 
elements, including age, patient attitude and expected 
treatment efforts, risks potentially associated with 
hypoglycemia or other adverse events, disease duration, 
life expectancy, comorbidities and established vascular 
complications as well as resources and support system 
[14]. 
 
Moreover, the most recent guidelines, while 
emphasizing individualization of HbA1c targets, 
underline that age per se should not be an excuse for 
suboptimal metabolic control [4,14,15]. Indeed, 
although attention has rightly been paid to the risks of 
over treatment of hyperglycemia in older subjects 
exposing them to the risk of hypoglycemia, treatment 
burden, increased risk of mortality, the potential 
negative impact of untreated or undertreated 
hyperglycemia, must be recognized even in patients 
with short life expectancy as a cause for dehydration, 
electrolyte abnormalities, urinary incontinence, 
dizziness, falls and overall poor outcome [4].  
 
Reaching the best risk-to-benefit ratio of anti-diabetic 
treatment in the elderly T2DM patients is, however, not 
a simple task as the heterogeneity of this population has 
not been yet fully addressed by proper clinical trials. 
Therefore, in this review, we will discuss pros and cons 
as well as limitation of information with respect to the 





The authors collected materials for this review from a 
search of PubMed using as filters keywords relating to 
T2DM management in older people. In addition, a 
manual review of the references lists from retrieved 
articles was also performed to find further articles. 
Papers were reviewed for relevance by abstract, 
selecting only English language articles. The final list of 
cited references was chosen on the basis of relevance to 
the topic of review.  
Epidemiology of diabetes in the elderly 
Ageing population is a growing problem and an 
important risk factor for several chronic diseases such 
as diabetes mellitus (DM) [16,17]. The prevalence of 
diabetes among US adults aged ≥65 years ranges from 
22% to 33%, depending on the diagnostic criteria used 
[18,19]. Current estimates indicate that in the US, 
26.9% of people ≥65 years of age are diagnosed with 
diabetes [20]. The high prevalence of T2DM among the 
elderly has been confirmed in a prospective population-
based study in The Netherlands, showing that elderly 
patients, aged 70 years and over, account for 50% of the 
type 2 diabetic population, supporting health-care 
planning for older people [21].  
 
As the population ages and both overweight and obesity 
continue to rise, the prevalence of diabetes in the elderly 
is expected to further increase [18,22,23] amplifying the 
already high burden of disease and its related costs [24]. 
Already today, the prevalence of diabetes in nursing 
homes is particularly high and care for diabetes in this 
setting specific is often inappropriate or insufficient 
[25,26]. Moreover, diabetes in the elderly is a well-
recognized cause of accelerated frailty, disability, 
hospitalization, institutionalization, and death, thus 
absorbing a growing fraction of healthcare resources 
[14,27,28].  
 
Overview on pathogenesis of diabetes in the elderly 
Aging is a process characterized by a multifaceted 
interaction of genetic, epigenetic, and environmental 
factors [29]. Genetic variants have been shown to 
impact on human longevity, showing a strict association 
with both unsuccessful aging and diabetes [29-31]. A 
strong genetic predisposition to T2DM in the elderly is 
apparent as well though only some candidate genes 
have been identified [32,33]. The pathogenesis of 
T2DM is characterized by two major mechanisms: 
impairedβ-cell function and insulin resistance [34]. The 
former is the main defect observed in lean older 
subjects, while obese older patients have relatively 
normal insulin secretion but marked resistance to 
insulin-mediated glucose disposal [35]. The 
Cardiovascular Health Study showed that the 
association between some risk factors and incident DM 
varied significantly depending on whether DM was 
preceded predominantly by insulin resistance, β-cell 
dysfunction, or both, thus suggesting putative subtypes 
of DM with biologic and clinical implications [36]. 
With aging, glucose-stimulated insulin response tends 
to decline, impaired insulin secretion pulsatility is lost, 
decreased sensitivity to incretins develops, andβ-cell 
mass is reduced [17]. Many events contribute to the 
age-related loss of β-cell mass and function, including 
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the age-associated mitochondrial dysfunction, as well as 
increased oxidative stress and inflammation [36-42].  
 
Aging results in a progressive loss of muscle mass and 
strength called “sarcopenia” that has a complex etiology 
involving neuronal, hormonal, immunological, nutritional 
and physical activity mechanisms [43,44]. Muscle mass 
loss in the elderly is associated with an increased fat mass 
infiltration that has been shown to be associated with 
worsened insulin sensitivity [45]. In this regard, in a 
recent cross-sectional study of 301 non diabetic subjects 
with a mean age of 65.9 years, a strong association 
between insulin resistance and relative muscle mass has 
been described [46]. Similarly, an association between 
sarcopenia and insulin resistance, diabetes, and metabolic 
syndrome has been reported in a large Korean 
population, particularly in elderly participants [47]. The 
link between sarcopenia and insulin resistance is a 
complex one, most likely mediated by several factors (i.e. 
mitochondrial dysfunction, reactive oxygen species, 
subtypes of adipocytes, fat-associated inflammation and 
adipocytokines) as recently reviewed [48]. Anyway, 
though sarcopenia may be not the primary cause of 
skeletal muscle insulin resistance in the elderly subjects, 
loss of lean muscle mass can be considered a worsening 
determinant.  
 



























activity all contribute to reduce insulin sensitivity in 
older population [49]. Glucose metabolism in older 
people can also be affected by co-existing illnesses and 
polypharmacy [33]. Finally, autoimmune phenomena 
may play a role in the pathogenesis of T2DM in a 
subset of older patients [50].  
 
Although understanding of the pathogenesis of type 2 
diabetes has advanced rapidly, the underlying molecular 
mechanisms remain partially unknown even because 
they are multiple, complex and linked each other. There 
is a huge progress in aging research on the role of the 
nutrient sensor mammalian target of rapamycin 
(mTOR) in aging and age-related diseases, including 
insulin resistance [51]. mTOR integrates multiple 
signals including growth factors, hormones, and cellular 
energy levels to regulate protein translation and cell 
metabloism, and survival, thus mediating the nutrient 
effects on insulin resistance. The attractive link between 
mTOR and insulin signaling cascades suggests that 
mTOR could become a therapeutic target in insulin-
resistant status, even if its clinical application in 
metablic diseases is still limited [51].   
 
In summary, diabetes in the elderly is the result of a 
tangled and still incompletely understood combination 
of genetic and environmental factors that overlap and 
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Special thoughts for elderly patients affected by type 
2 diabetes mellitus 
T2DM can be independently associated with various 
aging phenotypes collectively defined as “geriatric 
syndromes” [11,52-57]. These geriatric conditions 
should be referred to as a third category of diabetic 
complications [58] and include cognitive impairment 
and dementia [55,59-67], depression [68,69], reduced 
muscle strength and quality [70-72], disability [73-77], 
falls and fall-related morbidity [78,79], as well as 
urinary incontinence [80]. These clinical conditions are 
very frequent in older diabetic people, especially in the 
frail ones. When present they exert a negative effect on 
the quality of life, functional outcomes, and mortality 
[54,81-83]. Moreover, these impairments, in particular 
cognitive decline, can affect in a significant manner the 
(self)-management of diabetes [84,85]. The cognitive 
decline is likely to initiate early in the natural 
progression of diabetes and it correlates with overall 
glycemic control [86-88]. To emphasize the link 
between T2DM and cognitive function some authors 
have proposed Alzheimer's disease as a third form of 
diabetes [89]. The etiology of cognitive impairment in 
diabetic patients is multifactorial [90] with a role played 
by dysglycemia, microvascular disease, insulin 
resistance, hyper-phosphorylation of tau protein, 
amyloid-β deposition, inflammation and oxidative stress 
[91,92]. More recently a role for sirtuins has been 
claimed. Sirtuins belong to a family of highly conserved 
protein deacetylases that depend on nicotinamide 
adenine dinucleotide (NAD+) for their activity [93]. 
These proteins have been shown to influence the course 
of several neurodegenerative disorders by controlling 
transcription factor activity [94,95]. Expression of 
SIRT1, the best characterized member within the family 
of sirtuins, seems to be reduced in T2DM and in 
conditions of insulin resistance [96], while, its 
activation improves insulin sensitivity [97].  
 
Older diabetic people may be more vulnerable also 
because of coexisting comorbidities and related 
polypharmacy. Moreover, aging may be associated with 
changes in several pharmacokinetic and pharmaco-
dynamic parameters. These include reduction of renal 
and hepatic function and increased volume of 
distribution of lipid soluble drugs resulting in an 
increase of drug half-life [98-101]. Pharmacodynamic 
changes can cause drug accumulation in the circulation 
and intensified sensitivity, for instance, to sulfonylureas 
thus increasing the risk of hypoglycemia [98]. In this 
setting, aging per se is a strong predictor of 
hypoglycemia [102-104] and hypoglycemia, in turn, is a 
major complicating factor of antidiabetic treatment 
[105]. Impaired counterregulatory response and 
increased symptom threshold worsen the risk and 
outcomes of hypoglycemia in elderly diabetic patients 
[106-107]. The risk of such an event in the elderly can 
be by reduced or irregular eating pattern, intercurrent 
diseases and concomitant use of other drugs [108]. 
Patients on five or more medications, particularly if 
they include ACE-inhibitors and nonselective beta-
adrenoceptor antagonists, are more prone to drug-
induced hypoglycemia [102-103]. Altogether, the 
various degree of concomitance of these factors may 
account for the variable rate of hypoglycaemia in the 
elderly reported in the literature. In the ACCORD trial, 
each one year increment in baseline age was associated 
with a 3% increase in the risk for hypoglycaemia 
requiring medical assistance [109]. 
 
Hypoglycaemia in the elderly is associated with serious 
morbidity, including cardiovascular events, stroke, 
arrhythmias, and falls result in fractures on a 
background of osteoporosis [110-117]. Results of post-
hoc analyses of both the ACCORD and VADT trials 
have shown a strong association between severe 
hypoglycemia and cardiovascular mortality, especially 
in the elderly population [118]. In the ACCORD trial, 
intensive glucose lowering increased the risk of 
cardiovascular disease and total mortality in younger 
participants whereas it had a neutral effect in older 
participants, though the older subgroup had a greater 
annualized rate of severe hypoglycemic episodes [119]. 
Prevention of hypoglycemia requires identification of 
risk factors [102,113], patient and family education and 
reassurance regarding prevention, detection, and 
treatment of hypoglycemic events [4]. Reducing the risk 
of hypoglycemia should follow, in the elderly, the 
paradigm "start low and go slow" [100]. 
 
However, the heterogeneity of the older diabetic 
population must be fully appreciated [120] if adequate 
glycemic control has to be provided. Optimal care 
should balance health and function, tapering and 
tailoring the pharmacological approach in order to reach 
invidualized goals while avoiding clinical inertia. 
Biological rather than chronological age of the patient 
should be considered in defining therapeutic strategies 
[121]. Assessment of psychological age and social age 
is also recommended as part of a comprehensive (and 
multidisciplinary) geriatric appraisal of older people 
with diabetes in order to address the role of various 
comorbidities and polypharmacy before selecting 
treatment plans [122]. 
 
Diabetes treatment guidelines for the elderly 
Optimizing drug therapy is essential in the care of an 
older person. In line with the Quality Use of Medicines 
Framework, three key steps should be considered in 
drug prescription: 1) to identify the best treatment 
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(considering non-pharmacological measures whenever 
possible); 2) to select medicines cleverly (considering 
the possibility of serious adverse effects or drug-to-drug 
interactions); and 3) to use medicines based on the 
strongest clinical evidences [123]. Likewise, three 
subgroups of older patients should be considered: 1) 
those who are relatively healthy; 2) those with complex 
medical histories in whom self-care may be difficult, 
and 3) those with a significant comorbidities and 
functional impairment [124,125]. Therefore, clinicians 
caring for older diabetic patients have to solve a 
therapeutic puzzle: balancing the patient’s needs while 
taking into consideration health profile and glycemic 
goals and avoiding adverse effects. 
 
Past guidelines have often not been able to provide 
specific recommendation for older diabetic patients. The 
California Healthcare Foundation/American Geriatrics 
Society in collaboration with other medical organizations 
suggested that a reasonable HbA1c goal for “relatively” 
healthy elderly with good functional status should be ≤53 
mmol/mol (<7%). On the contrary, for frail adults or with 
life expectancy <5 years, and when the risks of intensive 
glycemic control appear to overcome the benefits, a 
target HbA1c of 64 mmol/mol (8%) is suggested 
[54,126,127]. The U.S. Department of Veterans Affairs 
and the U.S. Department of Defense (VA/DOD) diabetes 
guidelines were updated few years ago. The VA/DOD 
guidelines do not distinguish by age-group, but stratify 
glycemic goals based on comorbidity and life expectancy 
























suggests that the goals of treatment for older T2DM 
patients who are cognitively intact and have long life 
expectancy should be the same as those for younger 
subjects, while less stringent goals are suggested for 
those with limited life expectancy, advanced diabetes 
complications, or extensive comorbid conditions [14]. 
Recently, the International Association of Gerontology 
and Geriatrics, the European Diabetes Working Party for 
Older People, and the International Task Force of Experts 
in Diabetes recommended a target HbA1c range of 53-58 
mmol/mol (7-7.5%) should be aimed for (DCCT aligned) 
for older T2DM patients with a single system 
involvement (Evidence level 1+, Grade of 
recommendation A), while for frailer (dependent; 
multisystem disease; care home residency including those 
with dementia) patients at high risk of hypoglycaemia in 
whom symptom control and avoidance of metabolic 
decompensation is paramount, target HbA1c range 
should range between 60-69 mmol/mol (7.6-8.5%) 
(Evidence level 1+, Grade of recommendation A) [15]. In 
the attempt to provide a less dictated approach a 
pragmatic strategy based on four variables has been 
recently proposed: (A)ge, (B)ody weight, (C)omplica-
tions and (D)uration of disease (ABCD) [121]. In short, 
in younger patients the goal is minimizing the risk of 
long-term complications while in older patients, especial-
ly in the frail ones the goal is to minimize shorter-term 
geriatric syndrome and maximize quality of life [127].  
 
Determinants of glycemic control in elderly patients 
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Treatment options 
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Metformin acts primarily through insulin sensitization 
of the liver, thus reducing hepatic glucose output and, 
secondarily, improving peripheral insulin resistance 
[129]. The recent ADA/EASD position statement and 
the AACE/ACE guidelines recommend metformin as 
first line treatment drug, due to its effectiveness and low 
risk of hypoglycemia [14,130]. In line with these 
recommendations, EDWPOP clinical guidelines stated 
that “age per se is not a contraindication to metformin” 
(Evidence level 2++; grade of recommendation B) [15] 
with some reduction in all-cause and cardiovascular 
mortality as compared to sulfonylurea monotherapy 
[131]. Metformin can cause gastrointestinal side effects 
(i.e. nausea, diarrhea, vomiting, abdominal pain), 
usually related to rapid titration and high dose initiation 
[132]. These adverse effects, although transient, may be 
undesirable in older, frail, anorexic and underweight 
patients [133], and may represent a dose-limiting barrier 
[134]. Metformin can also result in poor vitamin B12 
status [135-137], which might accelerate cognitive 
dysfunction [138]. However, the main concern with 
respect to the use of metformin in the older adult with 
diabetes relates to the frequent existence of impaired 
renal function that should be regularly monitored in all 
patients on the drug [14,15,139]. EDWPOP guidelines 
recommend avoiding metformin “in patients with renal 
impairment and severe coronary, cerebrovascular or 
peripheral vascular disease” (Evidence level 2++; grade 
of recommendation B) [15] because of the risk of lactic 

























metformin and lactic acidosis may be coincidental 
rather than causal [140], and there is no evidence from 
prospective comparative trials or from observational 
cohort studies that the risk of lactic acidosis and lactate 
levels differ appreciably in patients taking metformin as 
compared to other glucose-lowering treatments [141]. 
In a recent cross sectional analysis, it has been 
demonstrated that in elderly diabetic patients with 
moderate to severe renal impairment, the prescription of 
oral anti-hyperglycemic treatments is frequent, although 
inappropriate or not recommended. Nonetheless, 
metformin was associated with lower cardiovascular 
event rates [142]. The dose of metformin should be 
reduced (by 50% or to half-maximal dose) in patients 
with a GFR 30 to 45 mL/min per 1.73 m2, and 
monitored at 3-month interval and the drug stopped for 
an eGFR <30 ml/min per 1.73 m2 [143,144]. 
 
Metformin continues to gain attention for potential anti-
cancer properties and neuro-protective effects, thus 
emerging as a novel therapeutic agent in aging-related 
diseases [132].   
 
Thiazolidinediones  
Thiazolidinediones (TZDs) are peroxisome proliferation 
activated receptor-gamma (PPAR-gamma) agonists that 
improve peripheral insulin sensitivity by increasing 
peripheral adipose tissue lipogenesis and reducing 
hepatic fat content and hepatic glucose production 
[145]. TZDs could be an appealing strategy in the 
























Cancer risk (?) 
 
Dose adjustment may 
be recommended in the 
elderly on loop 
diuretics and in those 
with an estimated 
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hypoglycemia in comparison with sulfonylureas [146]. 
However, the real use of TZDs in the elderly is limited 
by their potential side effects. As suggested by two 
large observational studies, women taking TZDs have 
an increased risk of fractures as compared to those 
treated with other oral anti-diabetic drugs [147,148]. 
Similarly, TZDs have been associated with a 
questionable risk of bladder cancer [149-151]. Finally 
an increased prevalence of congestive hearth failure has 
been reported in patients on TZDs [152]. More debated 
remain the association between TZD use and 
cardiovascular events. In a case-control study of a 
cohort of 159,026 patients aged ≥ 66 years, TZD 
therapy (primarily rosiglitazone) was reported to be 
associated with increased risk of congestive hearth 
failure, acute myocardial infarction and death as 
compared to other oral hypoglycemic agents [153]. 
These results have not been confirmed in other studies 
[154] while an observational study suggested that TZDs 
were not associated with increased mortality for cardiac 
events and congestive heart failure in older patients 
[155]. The PROACTIVE prospective study showed a 
modest reduction of cardiovascular end points 
associated with pioglitazone [156] especially in patients 
with no peripheral artery disease [157]. 
 
In a 6-month randomized, open-controlled trial, it was 
reported that treatment with pioglitazone in diabetic 
patients affected by Alzheimer disease was associated 
with improvement in both cognition and regional 
cerebral blood flow, suggesting that PPAR-gamma 
agonists may offer a novel strategy for treating 
cognitive dysfunction [158]. 
 
Anyway, TZDs should not be considered a first-line 
approach and should be avoided in patients at high risk 
of weight gain, peripheral edema, heart failure, and 




Alpha-glucosidase inhibitors (AGIs) specifically target 
postprandial hyperglycemia by reducing carbohydrate 
digestion and absorption [159]. The hypoglycemic 
effect of AGIs is non as powerful, lowering HbA(1c) by 
0.5-1%, but the risk of hypoglycemia, when they are 
used in monotherapy, is low, making these agents of 
interest in the elderly [35]. In older diabetic patients 
inadequately controlled on diet alone, acarbose has been 
associated with a significant reduction in HbA1c (-
0.6%) as well as in the incremental post-prandial 
glucose values (-2.1 mmol/L) and mean fasting plasma 
glucose (-0.7 mmol/L) as compared to placebo [160]. In 
patients on prandial insulin, a mismatch between peak 
serum glucose level and peak prandial insulin levels 
may occur, with a possible increased risk of 
hypoglycemia [98], but a randomized, open-label study 
comparing the efficacy and safety of preprandial insulin 
in combination with acarbose in elderly patients (≥60 
years) showed that addition of acarbose allows insulin 
adjustment from 30 min to immediately before meals, 
without affecting glycemic control, along with a low 
incidence of hypoglycemia [161]. However, the 
gastrointestinal adverse effects (i.e. abdominal bloating, 
flatulence, and diarrhea), frequent dosing, and relatively 
high costs [58] represent a limitation for the use of 
AGIs in geriatric patients  
 
Insulin secretagogues 
Insulin secretagogue therapy (sulfonylureas, SUs and 
glitinides) is commonly used in clinical practice. These 
agents may be utilized as first, second-line or adjunct 
therapy behind metformin for treatment of T2DM. SUs 
cause glucose independent closure of the ATP-sensitive 
K-channels and release of insulin by binding to the SUR1 
receptor on pancreatic beta cells [162,163]. Meglitinides, 
including repaglinide, have a similar mechanism but are 
partially glucose dependent and characterized by a rapid 
onset time and shorter duration of action [164,165]. 
EDWPOP guidelines for T2DM suggest adding an 
insulin secretagogue when glycemic targets have not 
been achieved or maintained (evidence level 1+; grade of 
recommendation B), avoiding glibenclamide in elderly 
persons (>70 years) with newly diagnosed T2DM 
because of marked risk of hypoglycaemia (evidence level 
1+; grade of recommendation A) [15]. Renal impairment, 
hepatic dysfunction, concomitant insulin therapy, recent 
hospitalization, advanced age, poor nutrition, cognitive 
decline and polypharmacy are the main risk factors of 
hypoglycemia [102,166]. However, difference in such a 
risk exists among SUs with gliclazide being associated 
with lowest rate of hypoglycemia. Therefore, gliclazide, 
glipizide and third generation SUs (i.e. glimepiride) have 
been suggested as preferred agents in the elderly 
[102,166,167]. Accordingly, the American Geriatric 
Society clinical guidelines suggest short acting anti-
diabetic agents to be preferred to longer-acting SUs 
[15,54]. 
 
A 24-week, randomized, open label, crossover trial, in 
elderly patients aged ≥65 years and in a subgroup of 37 
patients aged≥75 years showed that treatment with 
repaglinide was associated with fewer hypoglycemic 
events as compared with those treated with gliben-
clamide [168].  Nonetheless, the risk of hypoglycemia 
associated with the use of meglitinides is not trivial 
[169].  
 
Finally, cardiovascular profile of SUs is an important 
concern because of their possible effects on ischemic 
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preconditioning [170], though the true relevance of this 
phenomenon has not yet been fully demonstrated and it 
is largely based in animal studies. Nonetheless, in a 
retrospective analysis, an increase in overall mortality 
risk has been reported for sulfonylureas as compared to 
metformin [171]. To summarize, SUs should not be 
seen as first-line treatment choice in the elderly.  Were a 
sulfonylurea introduced, it should be prescribed with 
caution, usually starting at half the usual dose and to be 
titrated gradually while providing the person with 
diabetes and his/her relatives adequate education with 
respect to the risk of hypoglycemia.  
 
Incretins 
Dipeptidyl peptidase-4 inhibitors (DPP4-I), usually 
referred as gliptins, are a relatively novel class of oral 
anti-hyperglycemic agents that stimulate insulin 
secretion and suppress glucagon secretion in a glucose-
dependent manner [172,173]. Due to their efficacy, low 
risk of hypoglycemia and good tolerability, gliptin-
based therapy plays a novel role in the management of 
diabetes and appears a fitting and intriguing choice for 
older adults [152,174]. According to the DWPOP 
guidelines, DPP4-I should be considered as an add-on 
therapy to metformin when the use of a SU poses an 
unacceptable risk of hypoglycemia (evidence level 1+; 
grade of recommendation A) [15]. The potential 
benefits of DPP-4 in the elderly have been discussed in 
a number of reviews [2,58,169,175-177]. However, ad 
hoc studies to establish clinical efficacy of DPP4-I in 
elderly T2DM patients have been only recently 
performed. These trials confirm in these individuals as 
well significant reduction of HbA1c with no 
hypoglycemia, body weight gain or other side effects 
[178-186]. Trials have been also performed in patients 
with moderate and severe renal impairment. With 
appropriate dosage adjustment with the exception of 
linagliptin, which has no renal excretion, these studies 
too have confirmed a good benefit-to-risk ratio with no 
further loss in renal function nor increased rate of 
hypoglycemia [187-192]. In the recent INTERVAL 
study, a multinational, double-blind, 24 week trial, drug 
naïve or inadequately controlled diabetic patients aged 
≥70 years were randomly assigned to vildagliptin 
(patient mean age 75.1 yrs) or placebo (patient mean 
age 74.4 yrs) while setting individualized treatment 
targets on the basis of age, baseline HbA1c, 
comorbidities and frailty status [193]. Vildagliptin-
treated patients achieved targets in 52.6% of the cases 
versus 27% of placebo-treated group, with a significant, 
relevant reduction of HbA1c values and no emergence 
of new safety signals [193]. Vildagliptin is metabolized 
mainly in the liver so liver function monitoring should 
be recommended, even if a recent meta-analysis 
indicated that vildagliptin is not associated with 
increased risk of hepatic events [194]. In diabetic 
patients aged up to 80 years, linagliptin had significant 
glucose lowering effects, showing a well-tolerated 
profile, which may result particularly useful in the 
elderly [195-199]. In a recent randomized, double blind, 
parallel-group, multinational phase 3 study, including 
patients aged 70 years or older (mean age 74·9 yrs), 
linagliptin was effective in lowering glucose, with a 
safety profile similar to placebo [186]. Data on the 
safety and efficacy of saxagliptin in the elderly are 
limited. Karyekar et al performed a post hoc analysis of 
pooled data from five 24-week phase 3 trials including 
older patients aged ≥65 years [185]. Results showed that 
saxagliptin was effective and well tolerated either when 
used as monotherapy, as add-on therapy, or initial 
combination therapy with other anti-diabetes drugs. 
Hypoglycemia, not requiring medical intervention, was 
reported in 3.0% to 9.4% of patients taking saxaglipitn 
(0%-8.0% for comparators) while confirmed 
hypoglycemia occurred in 0% to 0.7% (0% to 0.7% for 
comparators) [185]. Similar results have been reported 
for aloglipitn (as monotherapy and co-administration 
with other anti-diabetic agents) in a pooled analysis of 
six randomized, double blind, placebo-controlled 
studies, comparing the efficacy and safety of alogliptin 
in elderly (mean age 70 yrs) and younger (mean age 
51.8 yrs) patients with type 2 diabetes mellitus [179]. 
The efficacy and tolerability of sitagliptin have been 
evaluated in a randomized, double blind, placebo-
controlled, parallel-group study in diabetic patients aged 
≥65 years (mean age 72 yrs). Although a relatively 
small number of subjects has been included, the study 
demonstrated that sitagliptin significantly improved 
glycemic parameters, with no hypoglycemia [184]. 
 
Over the last years more information on the potential of 
this class of oral agents have been gathered to further 
enhance the interest with respect to their use in elderly 
patients. Recent data suggest that gliptins may have 
pleiotropic, additional non-glycemic properties, 
including cardio- [200] and neuro-protective effects 
[201-204]. Cardiovascular (CV) safety of gliptins is a 
field of growing interest. In the SAVOR-TIMI trial 
while no effect on overall CV morbidity and mortality 
was reported, an excess of hospitalization for heart 
failure was observed [205]. This finding will require 
further assessment as absolute number of events was 
limited and an imbalance in the pro-BNP levels was 
present in the sitagliptin vs the control group with 
increased hospitalization occurred in the patients in the 
top pro-BNP quartile. Results from EXAMINE showed 
that among diabetic patients who had had a recent acute 
coronary syndrome, the rates of major adverse 
cardiovascular events were not different between 
patients on alogliptin as compared with those on 
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placebo [206]. Taken together, these data confirm a 
neutral cardiovascular safety profile in high CV risk 
patients, as often are older T2DM individuals.  
 
Glucagon-like peptide 1 (GLP-1) analogues include 
exenatide, liraglutide, and lixisenatide. These 
compounds may have a slightly greater effect on HbA1c 
as compared to DPP4-I, low risk of hypoglycemia and 
cause a moderate loss in body weight [207]. According 
to the DWPOP guidelines GLP-1 agonist may be 
considered as 3th line add-on therapy to metformin and 
SU (evidence level 2++, grade of recommendation B) in 
very obese older patients up to an age of 75 years) [15]. 
Data on these agents above this age, especially the frail 
patient, are scanty [98,208]. In a placebo-controlled, 
patient-blind, crossover study compared elderly patients 
(mean age 78 ± 3 yrs) to controls (mean age 57 ± 6 yrs) 
with T2DM, exenatide was tolerated in all age groups, 
and dosage adjustment was requested according to 
patient's renal function [209]. A pooled analysis of 6 
randomized, placebo-controlled, multinational trials 
included data from 3967 patients aged 18 to 80 years 
has shown that liraglutide provides effective glycemic 
control and is well tolerated in patients aged ≥65 years 
[210], although its use can be limited by concomitant 
impairment of the kidney function. Lixisenatide is the 
most recently approved GLP-1 receptor agonist 
[211,212], but less information, particularly in older 
T2DM patients, are available. Though preliminary data 
may suggest a potential neuro-protective effect 
[213,214], results of intervention trials are awaited. 
Importantly, clinical trials of the effects of GLP-1 
agonists in patients with neurodegenerative diseases 
have been started, and clinical trials in patients with 
mild cognitive impairment or early-phase Alzheimer 
disease are on their way.  
 
Although GLP-1 analogs are characterized by a 
favorable benefit-to-risk ratio, their use in the elderly 
should consider potential impairment of kidney function 
as well as gastric side effects. These compounds, though 
with some difference within the class, can cause nausea 
and vomiting and, therefore, may not be indicated in 
those elderly patients with erratic nutrition habits nor 
they may be recommended in those with lower body 
weight or progressive loss of body weight. 
 
Sodium-glucose co-transporter 2 inhibitors 
Sodium-glucose cotransporter 2 (SGLT2) inhibitors 
represent a novel approach to treat T2DM. The 
mechanism of action is unique and does not hinge upon 
beta-cell function or tissue insulin sensitivity [215,216]. 
Through SGLT2 inhibition, reabsorption of tubular 
glucose is reduced and urinary glucose excretion 
increased [217] with very low risk of hypoglycemia. 
Moreover, loss of glucose causes mild but persistent 
reduction in body weight and concomitant fluid loss can 
reduce blood pressure. In a randomized, double-blind, 
placebo controlled phase 3 study, the efficacy and 
safety of canagliflozin, at different dosage, have been 
evaluated in older diabetic patients, aged 55 to 80 years 
(mean, 63.6 years), which were inadequately controlled 
on their usual treatment regimen [218]. The study 
demonstrated good tolerability and significant 
amelioration of glycemic control, along with a reduction 
of body weight and systolic blood pressure [218]. The 
most common side effects of these drugs include 
genitourinary infections and pollakiuria while, effects 
potentially dangerous for the geriatric age, such as 
dehydration, is uncommon. To note that concomitant 
prostate hypertrophy has not been so far identified as a 
limitation for the use of these agents  [219,220]. Dose 
adjustment may be recommended in the elderly, those 
on loop diuretics, and those with an estimated 
glomerular filtration rate (eGFR) < 60 ml/min/1.73 m(2) 
if there are concerns or symptoms of volume-related 
side effects [221]. The efficacy of SGTL-2 inhibitors is 
likely to be self-limited in the presence of reduced GFR 
as this will be consensually associated with reduced 
tubular load and therefore reduced glucose excretion. 
Nonetheless, in a randomized, double-blind, placebo-
controlled, phase 3 trial, canagliflozin improved 
glycaemic control and was generally well tolerated in 
subjects with T2DM and stage 3 chronic kidney disease 
[222]. Though SGLT2 inhibitors appear to be an 
emerging, appealing treatment option in diabetes, the 
safety issue remains the most important parameter 
determining the future of these drugs and more studies 
are needed before specific suggestions for elderly 
patients can be made.  
 
Insulin 
The natural history of T2DM is characterized by a 
progressive decline in β-cell mass and function [223]. 
As a consequence, insulin therapy may be needed in 
older diabetic patients [98], also own to the anabolic 
effect the hormone. However, use of insulin requires 
special considerations in elderly patients. 
Comorbidities, cognitive dysfunction, vision loss, 
neuropathies, disabilities, and poor manual dexterity can 
all affect the patient’s ability to self-management of 
insulin and may be limiting factors to insulin use in 
some cases or require caregiver assistance. Indeed, 
clinicians should evaluate the social network of patients 
who may have difficulty administering insulin – 
including family, friends, and caregivers – and should 
also determine whether the patient is socially isolated 
and/or living alone [224]. On the other hand, data show 
that insulin initiation in poorly controlled diabetic 
patients can improve quality of life [225]. Insulin 
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initiation should be performed with caution and with 
defined targets to prevent worrisome adverse events, in 
particular hypoglycemia. As already stated, it is 
advisable to “start low and go slowly”, taking particular 
attention to insulin dose titration. Insulin requirements 
may be variable in elderly patients due to habits and 
pathophysiologic factors as well. While renal 
dysfunction may reduce renal insulin clearance and 
result in insulin accumulation with increased risk of 
hypoglycemia, concomitant use of other drugs can 
result in an increased insulin demand as it may occur 
with steroids. When oral agents fail to lower glucose 
levels adequately, insulin can be used either as 
monotherapy or in combination with a SUs or 
metformin (Evidence level 1+, grade of 
recommendation) [15]. Short acting insulin analogs (i.e 
insulin lispro, aspart, and glulisine) can help in the case 
of unpredictable eating habits or in those patients unable 
to adhere to dietary recommendations. Insulin dose can 
be titrated by carbohydrate intake also after meal when 
amount of carbohydrate ingested is erratic [224]. The 
long-acting basal insulin analogs (insulin detemir and 
glargine) represent by and large the most common 
choice for basal insulin therapy in elderly patients 
[14,15]. These analogs offer several advantages, 
including a more physiologic pharmacologic profile and 
they carry a reduced risk of hypoglycemia, particularly 
of nocturnal hypoglycaemia [226-228]. Focusing on 
elderly subjects, a pooled analysis of data from five 
randomized controlled trials showed that addition of 
insulin glargine to oral antidiabetic drugs in older adults 
(aged ≥65 years) with poor glycemic control was 
associated with greater reductions in HbA1c and fasting 
blood glucose and lower risk of nocturnal hypoglycemia 
as compared to NPH insulin [229]. Moreover, in a 
planned subgroup analysis of the original study, 
addition of once-daily morning glargine emerged as a 
simple regimen to initiate insulin therapy in elderly 
patients (aged 65 and older), restoring glycemic control 
more effectively and with less hypoglycemia than 
twice-daily 70/30 alone [230]. The new basal insulin 
analog, insulin degludec, has showed peculiar 
characteristics, including stable pharmacokinetic and 
pharmacodynamic profiles, true 24-hour duration of 
action in all patients, low within-person variability in 
absorption and glucose-lowering action, more flexible 
dose timing, and low occurrence of hypoglycemia 
[231]. In a recent pre-planned meta-analysis in elderly 
patients (≥ 65 years), the rate of confirmed and 
nocturnal hypoglycemia was significantly lower with 
insulin degludec as compared to insulin glargine [232]. 
Insulin premix formulations, in some elderly patients 
and in special settings, may provide added convenience 
[233]. Insulin pen devices may facilitate insulin 
injection and dosing and help patients maintaining their 
independence [224]. 
 
In summary, insulin remains the most effective and 
flexible form of treatment and as such it remains a 
valuable treatment opportunity in the elderly diabetic 
person, although insulin therapy in this group of 
subjects has not been adequately investigated. 
Moreover, the limited data comparing different insulin 
treatment schemes do not allow an evidence-based 
choice of insulin regimens in the elderly [234]. As 
repeatedly stated, careful individualization of insulin 
therapy as well is needed. While fast-acting insulin may 
be preferred to control post-prandial glucose, a carefully 
adjustment of dose on the basis of carbohydrate 
consumption is needed. Long-acting insulin can be 
easier to use though their long duration must be 
carefully taken into account as they may expose the 
elderly patient to the risk of late hypoglycemia. Careful 
education must be provided to the patient, his/her 
family and any person that may assist him/her. Finally, 
insulin may be necessary in concomitance with any 
intercurrent acute event, such as an infection, trauma, or 
surgical operation. 
 
Emerging drugs  
Recent observations showing that a family of enzymes 
called sirtuins can significantly extend life in various 
organisms has led researchers to believe that they may 
also be capable to control age-related metabolic 
disorders, including obesity and type 2 diabetes in 
humans. It is well known that Sirtuin-1 (SIRT1) may 
have anti-diabetic effects, modulating insulin secretion 
and improving insulin resistance through several 
mechanisms [235]. Therefore, identification of 
therapeutic agents capable of modulating the expression 
and/or activity of sirtuins is expected to provide 
promising strategies for optimizing diabetes care [235]. 
In this regard, in vitro and animal studies have 
demonstrated that synthetic compounds, which have 
potent SIRT1-activating power, may improve insulin 
sensitivity in peripheral tissues (skeletal muscle and 
liver), reduce plasma glucose, and increase 
mitochondrial capacity [236,237]. Because of the sirtuin 
family's role in aging and age-associated pathologies, 
elderly subjects may represent the target populations for 
the treatment with this new class of compounds. 
Recently, elderly volunteers (mean age 67.1 yrs; range 
61-77 yrs) were treated with SRT2104, a selective small 
molecule activator of SIRT1 or placebo once daily for 
28 days, exploring multiple pharmacodynamic 
endpoints [238]. In this trial, although any significant 
changes in OGTT were observed, it has been 
demonstrated a trend toward a slower increase in insulin  
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and C-peptide in the treated group [238]. The new 
molecule was generally safe and well tolerated and this 
observation supports further development of sirtuin 





In spite of the fact that elderly diabetic patients account 
for a great majority of the diabetic population, limited 
attention has been paid in clinical trials thus limiting the 
clinical evidence on which treatment guidelines may 
find ground. Indeed, randomized trials generally have 
excluded older diabetic patients, in particular the frail 
ones, and clinical guidance has been largely based on 
data obtained in younger (adult) populations, thus 
making the optimal therapy of T2DM in geriatric 
patients controversial. Older people with diabetes 
represent quite a heterogeneous population that is more 
likely to have comorbidities and geriatric syndromes, in 
addition to cardiovascular complications and hypo-
glycemia. A more appropriate treatment of the elderly 
T2DM patients would require accurate definition of the 
geriatric patient not only based on clinical needs but 
also encompassing healthy, social, economic 
parameters. Clinicians must be fully aware of this 
heterogeneity in setting the therapeutic goals and in 
choosing the therapeutic strategy, which, invariably, 
should be centered on the patient’s features, in line with 
the recent ADA/EASD position statement and in 
particular the ADA/AGS consensus document on 
diabetes in older adults [14,239]. These documents 
advocate a personalized and tailored care based on 
several elements, including patient’s attitude and 
expected treatment efforts, risks potentially associated 
with hypoglycemia or other adverse events, disease 
duration, life expectancy, comorbidities and established 
vascular complications as well as resources and social 
and familial support. What must be always appreciate, 
however, is that age per se should not be an excuse for 
"clinical inertia" because the risk generated by 
inappropriate hyperglycemia has to be considered in all 
patients also in those with short life-expectancy. The 
complexity of interactions between comorbidity, 
polypharmacy, aging and settings where the older 
T2DM adult may be living must suggest caution as 
reflected by the classic adage "start low + go slow". 
Yet, the targets and overall aim of the treatment should 
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